Patient with active or history of intraocular inflammation (e.g. iritis, uveitis), herpes simplex keratitis; aphakia, pseudophakia with torn posterior lens capsule or anterior chamber lenses; risk factors for cystoid macular oedema; angle-closure glaucoma, pigmentary glaucoma, congenital glaucoma, neovascular glaucoma. Pregnancy and lactation.
Adverse Reactions
Significant: Bacterial keratitis (when using multiple-dose containers), changed or increased brown pigmentation of iris and eyelid skin; changes in eyelashes and vellus hair (including increased length, thickness and number of lashes), intraocular inflammation and exacerbation of inflammation, macular oedema (including cystoid macular oedema), reactivation of herpes simplex keratitis. Cardiac disorders: Palpitations. Eye disorders: Ocular hyperaemia, eye pain, ocular discomfort, dry eye, eye pruritus, eye irritation, blurred vision, blepharitis, eyelid margin crusting, eyelid erythema, conjunctivitis, cataract, corneal staining, reduced visual acuity, photophobia, keratitis, increased lacrimation. Immune system disorders: Hypersensitivity reaction, seasonal allergy. Nervous system disorders: Headache. Respiratory, thoracic and mediastinal disorders: Cough, nasal congestion, throat irritation. Skin and subcutaneous tissue disorders: Skin hyperpigmentation (periocular), skin discolouration.
This drug may cause temporary blurring of vision or other visual disturbances, if affected, do not drive or operate machinery. Remove contact lenses prior to administration and reinsert them after 15 minutes.
Monitoring Parameters
Monitor IOP. Perform ophthalmic exams including optic nerve and visual field assessment.
Action
Description: Mechanism of Action: Travoprost, a synthetic analogue of dinoprost (prostaglandin F2α), is a highly selective full agonist with a high affinity for the prostaglandin FP receptor. Its exact mechanism of action has not been fully expounded; however, it appears to decrease intraocular pressure (IOP) by increasing the aqueous humour outflow through the trabecular meshwork and uveoscleral pathways. Onset: Approx 2 hours (IOP reduction). Duration: ≥24 hours (IOP reduction). Pharmacokinetics: Absorption: Absorbed through the cornea. Metabolism: Metabolised in the cornea via hydrolysis by esterases into active free acid; further metabolised systemically into inactive metabolites. Excretion: Via urine (<2% as metabolites). Elimination half-life: 45 minutes (range: 17-86 minutes).
Chemical Structure
Travoprost Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5282226, Travoprost. https://pubchem.ncbi.nlm.nih.gov/compound/Travoprost. Accessed Nov. 27, 2024.
S01EE04 - travoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.
References
Anon. Travoprost. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 08/11/2024.Brayfield A, Cadart C (eds). Travoprost. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/11/2024.Joint Formulary Committee. Travoprost. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/11/2024.Novartis New Zealand Limited. Travatan Eye Drops 0.004% data sheet 11 August 2023. Medsafe. http://www.medsafe.govt.nz. Accessed 08/11/2024.Travo 0.004% w/v Eye Drops, Solution (Gopharma Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 14/11/2024.Travoprost 40 micrograms/mL Eye Drops, Solution (Accord-UK Ltd). MHRA. https://products.mhra.gov.uk. Accessed 08/11/2024.Travoprost Solution (Apotex Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 09/11/2024.Travoprost. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 08/11/2024.
Sign Out
